Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Receivables (2022 - 2025)

Fennec Pharmaceuticals filings provide 4 years of Receivables readings, the most recent being $23.2 million for Q4 2025.

  • On a quarterly basis, Receivables rose 80.23% to $23.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.2 million, a 80.23% increase, with the full-year FY2025 number at $23.2 million, up 80.23% from a year prior.
  • Receivables hit $23.2 million in Q4 2025 for Fennec Pharmaceuticals, up from $19.3 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $23.2 million in Q4 2025 to a low of $1.5 million in Q4 2022.
  • Median Receivables over the past 4 years was $12.3 million (2024), compared with a mean of $11.0 million.
  • Biggest five-year swings in Receivables: surged 510.46% in 2024 and later skyrocketed 42.15% in 2025.
  • Fennec Pharmaceuticals' Receivables stood at $1.5 million in 2022, then skyrocketed by 470.49% to $8.8 million in 2023, then soared by 46.18% to $12.9 million in 2024, then skyrocketed by 80.23% to $23.2 million in 2025.
  • The last three reported values for Receivables were $23.2 million (Q4 2025), $19.3 million (Q3 2025), and $17.5 million (Q2 2025) per Business Quant data.